Homocysteine can be methylated to form methionine by the cobalamin-(Cbl) and folate-dependent enzyme, methionine synthase; serum levels of total homocysteine are elevated in greater than 95% of patients with either Cbl or folate deficiency. Homocysteine can also condense with serine to form cystathionine in a pyridoxal phosphate-dependent reaction catalyzed by cystathionine &synthase. Cystathionine is subsequently cleaved to cysteine and aketobutyrate by the pyridoxal phosphate-dependent enzyme y-cystathionase. To assess levels of cystathionine in Cbl and folate deficiency, we developed a new capillary gas chromatographic-mass spectrometric assay and measured cystathionine in the serum of normal subjects and patients with clinically confirmed deficiencies of these vi- Serum assays for metabolites involved in Cbl-and folate-dependent pathways have been found to be useful in For example, in Cbl deficiency, serum levels of methylmalonic acid, 2-methylcitric acid, and/or homocysteine are elevated in about 95% of patients.*-" In folate deficiency, serum-total homocysteine has been found to be elevated in 95% of patients.'.'"
I improving the specificity and sensitivity of the diagnosis ofcobalamin (Cbl) and folate Serum assays for metabolites involved in Cbl-and folate-dependent pathways have been found to be useful in For example, in Cbl deficiency, serum levels of methylmalonic acid, 2-methylcitric acid, and/or homocysteine are elevated in about 95% of patients.*-" In folate deficiency, serum-total homocysteine has been found to be elevated in 95% of patients. ' .'"
The reason for the elevated levels oftotal homocysteine in Cbl and folate deficiency is shown in Fig 1, which includes the transmethylation pathway where homocysteine is methylated to form methionine by a Cbl-dependent enzyme, methionine synthase, which simultaneously demethylates 5-CH,-tetrahydrofolate ( 5-CH3-THF) to form THF.'* Homocysteine can also be converted to methionine by a Cbl-and cally confirmed folate deficiency, cystathionine concentrations ranged from 138 nmol/L to 4.1 50 nmol/L (median = 1,560 nmol/L) and 19 (95%) had values above the normal range. Five homozygotes for cystathionine &synthase deficiency had high values for serum-total homocysteine and low or low-normal values for serum cystathionine that ranged from 30 nmol/L to 114 nmol/L even though they were on treatment with pyridoxine and had partially responded. One patient with a defect in the synthesis of 5-CH,-tetrahydrofolate and five patients with defects in the synthesis of CH3-Cbl had high values for serum-total homocysteine and high values for cystathionine that ranged from 31 1 nmol/L to 1,500 nmol/L even though they were on treatment with folic acid and Cbl, respectively, and had partially responded. We conclude that levels of cystathionine are elevated in the serum of most patients with Cbl and folate deficiency and that they are useful in the differential diagnosis of an elevated serum-total homocysteine level.
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folate-independent enzyme, betaine-homocysteine methyltransferase, which simultaneously converts betaine to N,N-dimethylglycine.I2 However, deficiencies of Cbl and folate are not the only causes of elevated serum-total homocysteine concentrations. As can also be seen in Fig I, in a pathway referred to as transsulfuration, homocysteine and serine are condensed by an enzyme, cystathionine 0-synthase, to form cystathionine." This enzyme is pyridoxal phosphate (vitamin B,)-dependent and in conditions of pyridoxine deficiency13 or in congenital defects of cystathionine ,&synthase, serum and urine homocysteine levels are e1evated.'"l6 Cystathionine is cleaved by another pyridoxal phosphate-dependent enzyme, y-cystathionase, to form cysteine and a-ketobutyrate. Cysteine is then converted to taurine, or used in glutathione or protein, or degraded chiefly to inorganic sulfate. Therefore, homocysteine is at a branch point where it can either be methylated to form methionine or converted to cystathionine and then to cysteine. Methionine can be activated to an important physiologic methylator, S-adenosylmethionine. After the transfer of the methyl group, S-adenosylhomocysteine is formed, which is then hydrolyzed by S-adenosylhomocysteine hydrolase to form homocysteine."
The balance between transmethylation and transsulfuration is tightly regulated under normal conditions. Studies with normal human subjects have shown that homocysteine is cycled through to methionine several times before going irreversibly through the transsulfuration pathway." Conditions of excess methionine increase cystathionine P-synthase activity, and methionine depletion results in decreased cystathionine P-synthase a~tivity.'~.'~ The balance between transmethylation and transsulfuration in Cbl-or folate-deficient patients has not been well studied. There are reports of increased urine cystathionine levels from a moribund infant with dietary Cbl deficiency*' and a child with a defect in Cbl absorption. 21 Tissue and serum levels of cys- [CYSTEINE] a-KETOBUTYRATE tathionine were elevated also in Cbl-deficient pigs.22 In patients with congenital defects of Cbl metabolism or 5, IO-methylene-THF (5, IO-CH,-THF) reductase deficiency, cystathionine levels have been found to be both in~r e a s e d~~,~~ and n~r m a l .~~,~~ These reports are interesting because in Cbl-deficient ratsz7 and in a patient with 5, IO-CH,-THF reductase deficiency,26 liver cystathionine &synthase levels were decreased although total flux through this pathway may have been normal because ofelevations of total homocysteine. Cystathionase activity was not determined in either of these two studies.
Patients with a congenital defect of cystathionase have high levels of cystathionine in both urine2* and p l a~m a~~.~' and occasionally have elevations also of homocystine. Pyridoxine deficiency causes increased levels of cystathionine in urine.31s32 Other causes of increased cystathionine excretion include preterm infants who have decreased or absent levels of cystathionase thyrotoxic patients,35 and patients with tumors of neural crest origin,36 hepatomas, and patients with severe liver di~ease.~'
All of the studies cited previously have been hampered by the lack ofsensitivity ofthe methods ofanalysis of cystathionine. The techniques used in the past have included paper or ion-exchange chromatography and detection using ninhydrin3sp39 and high performance liquid chromatography (HPLC) with derivatization by ~-phthaldialdehyde.~~ These methods are not sensitive enough to detect cystathionine in the serum of normal subjects. Normal ranges reported for urine levels commonly range from 0 on up, and as many as 179b3' of normal subjects are said to have undetectable levels of cystathionine in their urine. Another problem with the urine assay, as pointed out by Levy and Mudd?' is that bacterial contamination can result in cystathionine being converted to homocysteine, confusing the diagnosis.
We have adapted our capillary gas chromatography/mass spectrometry method for sulfur amino to assay cystathionine and have been able to determine the normal range for cystathionine in serum as well as levels in patients with Cbl deficiency, folate deficiency, and congenital defects of various enzymes involved in the homocysteine and cystathionine pathways.
MATERIALS AND METHODS
Assay of cystathionine. Cystathionine containing four deuterium atoms and designated as D,L-[2-amino-2-carboxyethyl]-homocysteine 3,3,4,4-D4 (98% enriched with deuterium) was obtained from MSD Isotopes (Montreal, Canada). The assay is based on the stable isotope dilution principle using the ratio of unlabeled cystathionine to labeled cystathionine. Because the latter is added to samples in known amount, it is not necessary to calculate recoveries that can vary from sample to sample. The following components were each added in sequence to 12 X 75 mm test tubes: (1) 5 1 FL of H,O containing 400 pmol of cystathionine containing 4 deuterium atoms (see above); ( 2 ) 400 pL of serum or urine (in the case of urine, 40 pL was used together with 360 p L of 0. I5 mol/L NaCI; (3) 1 mL of H,O, and (4) 51 pL of 1 N NaOH containing 10 mg/mL of dithiothreitol. The samples were mixed by vortexing, incubated at 40°C for 30 minutes, and then applied to 0.9 X 6 cm columns containing 400 pL (100 mg dry weight) of an anion exchange resin (AG MP-I, 100 to 200 mesh, chloride form) (BioRad Laboratories, Richmond, CA) that had previously been washed with 1 mL of For personal use only. on October 30, 2017. by guest www.bloodjournal.org From 3406 STABLER ET AL methanol and 3.3 mL of H,O. After the samples were applied, each column was washed three times with 3 mL of H,O and one time with 3 mL of methanol. Each column was then eluted with I. I mL of 0.4 N acetic acid in methanol. The eluates were taken to dryness by vacuum centrifugation in a vacuum centrifuge (Savant Industries, Inc, Hicksville, NY). The dried eluates were then derivatized by adding 30 pL of a solution containing 10 pL of N-methyl-N (tert-butyldimethylsilyl) trifluoracetamide (Pierce Chemical Co, Rockford, IL) and 20 pL of acetonitrile. After incubation at 90°C for 30 minutes in sealed autosampler vials, I pL was analyzed by gas chromatography/mass spectrometry using a 20-m SPB-1 capillary column (Supelco, Inc, Belfonte, PA). It had an internal diameter of 0.25 mm and a 0.25-pm film thickness.
Gas chromatography/mass spectrometry was performed using a Hewlett-Packard (Palo Alto, CA) 5890 Gas Chromatograph equipped with a 7673A Autosampler and a Hewlett-Packard 597 IA (or 5970B for complete spectra) Mass Selective Detector. The column-head pressure was 150 psi. The initial column temperature was 140°C, which was held for approximately 0.5 minute after sample injection and then increased to 320°C at a rate of 30°C/ minute. The mass-selective detector was operated in the selected ion monitoring mode in which the ion mass/charge (M/Z) 362.2 was monitored for endogenous cystathionine and ion M/Z 366.2 was monitored for cystathionine containing four deuterium atoms. Cystathionine was quantitated by dividing the integrated area ofthe M/Z 362.2 peak that eluted at approximately 6.74 minutes (the exact times were determined daily with controls) by the integrated area of the M/Z 366.2 peak that eluted at the same time and then multiplying by 1,000 nmol/L, which is the equivalent amount of the cystathionine containing four deuterium atoms that was added to each sample. Other amino acids such as homocysteine, methionine, and cysteine could be assayed at the same time if known amounts of their internal standards were added to samples at the same time as the internal standard for cystathionine. Details concerning the assay of these amino acids by gas chromatography/mass spectrometry have been provided p r e v i o u~l y .~~-~~ Subjects and patients. Serum samples from 50 normal healthy nonfasting blood donors, 25 men and 25 women ranging in age folate values, normal or elevated serum Cbl values, megaloblastic BM morphology, appropriate hematologic abnormalities, and responses to folic acid therapy. All had elevated levels of total homocysteine that ranged from 40.2 pmol/L to 257.4 pmol/L with a median of 64.2 pmol/L. Samples from 15 patients with renal failure were selected solely on the basis that their serum creatinine was elevated (range 1.7 to 12.5 mg/dL). Samples were also obtained from patients that were homozygotes for cystathionine @-synthase deficiency, 5, IO-CH,-THF reductase deficiency, and the mutations resulting in decreased synthesis of both adenosyl-Cbl and CH,-Cbl designated as Cbl C and Cbl D subtypes. The diagnosis of cystathionine 0-synthase deficiency was based on criteria that included elevated serum levels of homocystine, total homocysteine and methionine, direct enzyme assays on cultured fibroblasts, and the presence of ectopic lenses. The diagnosis of 5, IO-CH,-THF reductase deficiency was based on an elevated serum homocystine, a low serum methionine, and direct enzyme assays on cultured fibroblasts. The diagnosis of the Cbl C and Cbl D mutations was based on elevated serum levels of methylmalonic acid and homocystine together with complementation studies performed on the patients' fibroblasts.12 All of the patients with cystathionine @-synthase deficiency were on pyridoxine and patients B through E were also on folic acid and betaine at the time of our analyses. The patient with 5,10-CH2-THF reductase deficiency was on folic acid and betaine and the Cbl Cand D mutants were on parenteral Cbl and betaine at the time of our analyses.
RESULTS

Capillary gas chromatography/mass spectrometry.
When 5 nmol of cystathionine was derivatized directly with N-methyl-N[tert-butyldimethylsilyl] trifluoracetamide and analyzed by capillary gas chromatographylmass spectrometry, a single peak was observed that eluted at approximately 6.74 minutes. The mass spectrum for cystathionine is shown in Fig 2, together with the structure ofthe fullyderivatized cvstathionine molecule which contains a tert-butvldifrom 18 to 65 years, were obtained from the Belle Bonfils Blood Bank, Denver, CO, at the time of blood donation. The samples were obtained between 9:OO A M and 3:OO PM, were allowed to clot at room temperature for 1 hour and centrifuged at 1,500g for 30 minUtes at 4"C, and the serum was removed and stored at -20°C.
Spot urine samples were collected from the same 50 individuals within 30 minutes ofthe time the blood samples were obtained and methyisilyl group attached to each of the two car{oxyl groups and the two amino groups for a total of four such groups. Major ions were present at M/Z 190,202,244,258, 272,302,362, and 62 I. The mass spectrum obtained for the cystathionine containing four deuterium atoms was very similar to its unlabeled counterpart except that the ions with were also stored at -20°C. The urinary clearance of cystathionine as a percent of the urinary clearance of creatinine was determined with the following expression:
Samples from 30 patients with Cbl deficiency and 20 with folate deficiency were selected from an extensive serum collection that has been assembled at Columbia University over the past 20 years. Many, but not all, of the samples were obtained after an overnight fast. The diagnosis of Cbl deficiency was based on low serum Cbl levels, megaloblastic bone marrow (BM) morphology, appropriate hematologic or neurologic abnormalities, and a significant response to treatment with parenteral Cbl. All had elevated levels of total homocysteine that ranged from 18.5 pmol/L to 223.1 pmol/L, with a median of 85.6 pmol/L. Cerebrospinal fluid (CSF) was obtained from patients with neuropsychiatric disorders caused by lack of Cbl. The diagnosis of folate deficiency was based on low serum M/Z 202, 362, and 62 I were shifted upward by four mass units, and the ions with M/Z 244 and 272 were shifted upward by three mass units, indicating that these ions contain all or a portion of carbons 3 and 4 of the homocysteine moiety where the four deuterium ions are located (see legend to Fig 2) . Ions with M/Z 190, 258, and 302 were not shifted upward, indicating that these ions do not contain carbons 3 or 4 of cystathionine. A large number of serum and urine samples were analyzed with and without the addition of known amounts of cystathionine containing four deuterium atoms to determine which of the 2021206, 3621 366, and 62 11625 ion pairs were suitable for quantitating endogenous cystathionine in biologic samples. The 3621366 and the 62 11625 pairs provided the cleanest chromatograms and the 3621366 ion pair was chosen for routine analyses because the abundance of these ions was somewhat greater than the abundance of the 62 11625 ion pair.
A typical chromatogram from a normal serum sample is shown in Fig 3. Essentially identical chromatograms were obtained with urine (data not presented). Differences in values for cystathionine were not observed among blood samples that were stored at room temperature for 0, 1,4, or 24 hours before they were centrifuged and the serum removed. Differences were not observed between serum and plasma obtained with EDTA or heparin. Serum samples and the internal standard for cystathionine were stable for more than 1 year based on their chromatographic-mass spectrometric behavior when stored at -20°C despite numerous freezings and thawings over this time period. When assayed 24 times over a 2-month period, high and normal control samples containing cystathionine levels of 1,920 nmol/L and 140 nmol/L gave coefficients of variation of 3.5% and 6.896, respectively. When a pooled normal serum containing a level of cystathionine of 110 nmol/L was spiked with sufficient cystathionine to increase the concentrations to 260,410, and 610 nmol/L, recoveries of 94.5%, 95.8%, and 94.0% were obtained. When serum total homocysteine was assayed simultaneously, ion pair M/Z 420/424 was used and both ions eluted at approximately 4.78 minutes. When assayed 11 times over a 6-month period, a normal control sample containing a total homocysteine level of 8.0 pmol/L gave a coefficient of variation of 5.3%.
Cystathionine was readily detectable in the serum and urine from each of 50 normal blood donors. The normal range for human serum was calculated as 65 to 301 nmol/L, which is the mean f 2 SD after log normalization to correct for the skewness of the data toward higher values, with a median of 126 nmol/L. The normal range for urine was calculated as 350 to 49,900 nmol/L and as 100 to 2,960 when expressed as nanomoles of cystathioNormal subjects. nine per millimole of creatinine. The urinary clearance of cystathionine averaged 50.9% of the clearance of creatinine in the 50 normal subjects based on spot urines that were collected within 30 minutes of the time that serum samples were obtained. This is much higher than the value of 0.4% obtained for total homocysteine on the same samples. Cystathionine was barely detectable in CSF from normal subjects at levels of less than 30 nmol/L. This is in contrast to levels of CSF methylmalonic acid and 2-methylcitric acid that are higher in the CSF than they are in Patients with Cbl deficiency, folate deficiency, or renal failure. The values obtained for serum cystathionine in 30 patients with clinically confirmed Cbl deficiency and 20 patients with clinically confirmed folate deficiency are shown in Fig 4 together with those of the 50 normal blood donors. Twenty-six of the 30 Cbl-deficient patients (87%) had elevated levels. Values for the 30 patients ranged from a low of 208 nmol/L to a high of 2,920 nmol/L with a median of 8 16 nmol/L. In these patients, cystathionine did not correlate significantly with serum-total homocysteine concentrations ( r = .30, P > .05) or with serum methylmalonic acid levels ( r = .15). There were no significant differences in any of these determinations between the 15 Cbl-deficient patients with neuropsychiatric abnormalities and the 15 without such abnormalities. In the 15 patients with neuropsychiatric disorders caused by Cbl deficiency, the severity of neurologic impairment, as quantitated using a recently published method for calculating severity scores,4' did not correlate significantly with cystathionine, total homocysteine, or methylmalonic acid. Cystathionine could be detected in the CSF of patients with Cbl deficiency but the levels were only modestly elevated in the 30 to 200 nmol/L range. This is in Chromatogram of the tert-butyldimethylsylyl derivative of cystathionine from a 400-pL sample of normal human serum. The internal standard, which consisted of 400 nmol of cystathionine containing four deuterium atoms in place of four hydrogen atoms, was added to the sample before its being prepared for analysis by capillary gas chromatography/mass spectrometry as described in Materials and Methods. The mass spectrometer was operated in the selected ion monitoring mode and recorded values for M/Z 362.2 for endogenous cystathionine (A) and M/Z 366.2 for the internal standard of cystathionine (B). Values for abundance are relative arbitrary units. The value that was determined for cystathionine in this serum sample was 162 nmol/L. contrast to CSF levels of methylmalonic acid and 2-methylcitric acid that are markedly elevated in Cbl deficiency.''*44
Nineteen of the 20 folate-deficient patients (95%) had elevated serum cystathionine levels. Values for the 20 patients ranged from a low of 138 nmol/L to a high of 4,150 nmol/L with a median of 1,560 nmol/L. In these patients, serum Cystathionine correlated modestly with total homocysteine levels ( r = .51, P < .05).
No significant correlations were observed between the serum cystathionine concentrations and the hematocrit, mean corpuscular volume (MCV), age, sex, serum Cbl, serum folate, or serum methionine levels in either the Cblor folate-deficient patients. Table 1 shows serial levels of serum cystathionine in a patient with Cbl deficiency and in a patient with folate deficiency before and during treatment with parenteral cyano (CN)-Cbl and oral folic acid, respectively. Serum cystathionine levels decreased promptly and markedly in both patients but the decreases were not as linear as the decreases in total homocysteine that are also shown in Table 1 . This lack of linearity in the cystathionine response has also been observed in other patients with Cbl and folate deficiency (data not presented). Table 2 shows levels of serum cystathionine in 15 patients with renal failure. Levels of serum cystathionine were increased in all 15 patients, although only 7 had elevations of total homocysteine. Table 3 shows levels of cystathionine and related metabolites in patients with elevated serum total homocysteine levels caused by inherited deficiencies of enzymes that are closely related to the cystathionine pathway. In three of five homozygotes for cystathionine 0-synthase deficiency, serum cystathionine concentrations were low and in the remaining two, the values were in the lower part of the normal range. The peak eluting with M/Z = 362.2 at 6.74 minutes in these patients appears to represent cystathionine because coeluting peaks ofM/Z = 202.2,244.2,272.2, and 62 I .4 were also observed in the appropriate proportions (see Fig 2) when additional analyses were performed with sera from patients B and D. It should be noted that patients A through E in Table 3 were receiving therapy and all had partially responded to pyridoxine with a decrease in their methionine and total homocysteine levels before our assays. In addition, there was an inverse relationship between the levels of cystathionine and those of methionine and total homocysteine in these treated patients. Thus, even lower levels of serum cystathionine might be observed in untreated patients because pyridoxine
Patients with congenital enzyme defects. * The Cbl was administered as 1 -mg intramuscular injections of CNCbl on days 0, 3, 7, and 13. The folic acid was administered orally at a dose of 1 mg on days 0, 1, 2, 3, 4, and 5.
t The Cbl-deficient patient was a 32-year-old white man with pancytopenia, megaloblastic BM findings, a serum Cbl of 43 pg/mL, serum anti-intrinsic factor-blocking antibodies and an abnormal Schilling test that corrected with exogenous intrinsic factor. * The folate-deficient patient was a 45-year-old black woman with a hematocrit of 6%, MCV 141 fL. macroovalocytes and up to 10-lobed neutrophils on blood smear, serum folate 1 .O ng/mL, serum Cbl 640 pg/mL, serum creatinine 2.2 mg/dL, and severe alcoholic liver disease.
is thought to act by increasing the activity of cystathionine P-synthase. Although this might lead to an increase in serum cystathionine levels toward or within the normal range, it is important to note that this has not been shown. Cystathionine assays before and after therapy with pyridoxine would clearly be of interest. There was no overlap between the cystathionine levels observed in the five homozygotes and any of the 30 Cbl-deficient patients or the 20 folate-deficient patients. In contrast, the homozygote for 5,10-CH2-THF reductase deficiency, the three patients with the Cbl C mutation and the two patients with the Cbl D mutation all had elevated levels of serum cystathionine that ranged from 3 1 1 nmol/L to 1,500 nmol/L. The degree of elevation was very similar to that observed in the patients with Cbl or folate deficiency. The values might have been even higher had they been studied before therapy. Table 3 also shows serum cystathionine levels in four obligatory heterozygotes for cystathionine /3-synthase deficiency and two obligatory heterozygotes for 5 , IO-CH,-THF reductase deficiency. The cystathionine levels were all within the normal range as were the total homocysteine levels, with the exception of one heterozygote for cystathionine &synthase deficiency who had a modest elevation of total homocysteine.
Animal species. A preliminary survey of nine different animal sera showed that humans have the lowest levels of serum cystathionine (mean = 140 nmol/L for 50 normal 
DISCUSS ION
We have developed a new and sensitive assay for serum cystathionine and have determined a normal range for human serum. We have also shown that the majority of patients with Cbl deficiency and folate deficiency have levels of serum cystathionine at least 2 SD above the mean of normal blood donors. Serum cystathionine levels may be clinically useful in patients with Cbl and folate deficiency, because they were elevated in 87% and 95%, respectively. The serum cystathionine level can be added to the serumtotal homocysteine, methylmalonic acid, and 2-methylcitric acid concentrations as biochemical markers for Cbl or folate deficiency, with all four metabolites being elevated in most patients with the former and only cystathionine and total homocysteine being elevated in the latter.'," We have also shown that serum cystathionine levels in a Cbl-deficient patient and in a folate-deficient patient decrease in response to treatment. Because cystathionine levels are elevated in both folate and Cbl deficiency, they will not help in distinguishing between these two deficiency syndromes.
Additional clinical studies will need to be performed using measurements of serum cystathionine as well as total homocysteine, methylmalonic acid, and 2-methylcitric acid to determine whether they are comparable in sensitivity and specificity in diagnosing Cbl and folate deficiency, especially in patients with borderline or normal-serum Cbl or folate levels and minimal or mild clinical abnormalities. We * All patients had normal serum Cbl and folate levels except for patient 12 who had a serum Cbl of 140 pg/mL. t The numbers in parentheses refer to the patient numbers in Table 4 of Allen et all' that contains values for methylmalonic acid and 2-methylcitric acid on the same serum samples.
For found that the mean serum cystathionine level in a group of Cbl-deficient patients with neurologic abnormalities caused by Cbl deficiency was equal to that of a group of deficient patients without neurologic abnormalities. Thus, these levels will not be useful in determining whether neurologic abnormalities in patients with Cbl deficiency are related to the deficiency state or caused by other causes. This finding may indicate that abnormalities in cystathionine metabolism are probably not responsible for or play a prominent role in the pathophysiology of the central nervous system abnormalities caused by Cbl deficiency.
The relationship between homocysteine transmethylation and transsulfuration appears to be tightly regulated in normal humans and Under normal conditions, humans methylate homocysteine more than once before sending it through the transsulfuration pathway." In animal studies, it has been shown that excess methionine in the diet causes an increase in transsulfuration18 and methionine-deficient diets result in increased cycling of homocysteine to methionine with a decrease in transsulf~ration.~~ The latter would conserve methionine that, in its activated form as S-adenosylmethionine, is the major physiologic methyl donor for reactions catalyzed by over 100 enzymes that play important roles in DNA, RNA, protein, and lipid metab~lism?~.~' S-adenosylmethionine appears to be the major regulator of the transmethylation and transsulfuration pathways because it stimulates the activity of cystathionine @-synthase4* and inhibits the activity of 5,10-CH2-THF reductase49 that converts 5,10-CH2-THF to 5-CH3-THF and is the only source of this form of folate. Thus, when excess methionine and S-adenosylmethionine are present, cystathionine @-synthase will be more active and methionine synthase will be less active, and transsulfuration will be favored with the increased conversion of homocysteine to cystathionine and then to cysteine and a-ketobutyrate. On the other hand, when methionine and S-adenosylmethionine are scarce, cystathionine &synthase will be less active and methionine synthase will be more active (because of higher levels of 5-CH3-THF) and more homocysteine will be metabolized by transmethylation to replenish methionine and S-adenosylmethionine levels. The reciprocal effects that S-adenosylmethionine has on cystathionine @-synthase activity and methionine synthase activity help explain why homocysteine is markedly elevated in most patients with deficiency of either Cbl or folate. The resultant marked elevation of homocysteine is physiologic and important because it partially restores the activity of methionine synthase and maintains methionine levels within the normal range in almost all such patients as assessed by serum methionine level^.^
The physiologic significance and the explanation of the elevated cystathionine levels that occur commonly in Cbl and folate deficiency are both unclear. Although the concentration of cystathionine @-synthase enzyme activity would be expected to be decreased in Cbl and folate deficiency (see above), it is important to note that the total daily flux of homocysteine to cystathionine is probably maintained at normal levels in most patients, because their daily For personal use only. on October 30, 2017. by guest www.bloodjournal.org From methionine intake probably remains unchanged and because the major catabolic pathway for methionine via homocysteine, cystathionine, and cysteine to inorganic sulfate appears to be intact in patients with the Cbl D mutation2' and those with 5,lO-CH2-THF reductase deficiency.m The maintenance of a normal flux of homocysteine to cystathionine appears to result from the increased levels of total homocysteine, which is still well below its Michaelis constant (Km) for cystathionine P-synthase of 1 to 25 mmol/ L,46 and thus they compensate for the decrease in the concentration of cystathionine ,&synthase enzyme activity, which may be caused by changes in the number of enzyme molecules and/or a decrease in the concentration of an effector metabolite such as S-adeno~ylmethionine~~ and/or an increase in the concentration of an unknown inhibitor metabolite. If the total daily flux of cystathionine to cysteine is also maintained in most patients with Cbl or folate deficiency, as appears likely (see above), then the increase in serum cystathionine levels that we have observed would appear to be caused by a decrease in the concentration of ycystathionase enzyme activity, especially because the minor alternative pathways for cystathionine metabolismI2 do not appear to play a prominent role in patients with the Cbl D mutation2' and those with 5, IO-CH,-THF reductase deficiency." The elevated levels of serum cystathionine that we have observed in patients with Cbl and folate deficiency are still well below its Km for y-cystathionase of approximately 3 m m~l / L~~ and thus the elevated cystathionine levels could compensate for a decrease in the concentration of y-cystathionase enzyme activity and maintain a normal flux of cystathionine to cysteine. The mechanism by which the concentration of y-cystathionase enzyme activity would be reduced in Cbl and folate deficiency is unknown, and it could be caused by a decrease in the number of enzyme molecules or to changes in the levels of unknown enzyme effectors or inhibitors. Experiments designed to explore these possibilities and to document our hypothesis that the concentration of y-cystathionase enzyme activity is decreased in patients with Cbl and folate deficiency are in progress in our laboratories. It is interesting that both cystathionine B-synthase and y-cystathionase are pyridoxal phosphate dependent (see Fig 1) . Thus, if the availability of pyridoxine or pyridoxal phosphate is regulated with respect to both enzymes, this could effect parallel increases or decreases of the concentration of activities of both enzymes and could explain the elevation of cystathionine concentration in Cbl and folate deficiency if the level of y-cystathionase enzyme activity became rate limiting during periods of pyridoxine deprivation.
In addition to Cbl and folate deficiency, serum total homocysteine levels are elevated in a variety of other conditions that include inborn errors ofCbl transport and metabolism, inborn errors of folate transport, pyridoxine deficiency, and deficiencies of the enzymes cystathionine ,&synthase and 5 , IO-CH,-THF r e d u~t a s e . '~~~' Patients with elevated serum total homocysteine levels are being looked for and recognized with increased frequency, because a large number of recent studies have shown that elevated total homocysteine levels are strongly correlated with a variety of vascular diseases including stroke, heart attacks, and peripheral vascular d i~e a s e .~~"~ The recognition of the cause of an elevated total homocysteine level is important because treatment with Cbl, folic acid, or pyridoxine will each be effective in some, but not all, of the causes of an elevated serum total homocysteine, as enumerated above. Our studies indicate that serum cystathionine levels may be useful in the differential diagnosis of an elevated serum total homocysteine level, because patients who are homozygous for cystathionine P-synthase deficiency had low or low-normal levels of serum cystathionine that did not overlap with the mid-normal to elevated levels observed in the Cbl-and folate-deficient patients. Serum cystathionine levels were not useful in distinguishing the few heterozygotes for cystathione P-synthase deficiency that we studied from normal subjects, but they may be useful in methionine load studies where the degree of elevation of serum-total homocysteine can distinguish most but not all heterozygotes from normal subje~ts.'~,'~ Preliminary studies performed in our laboratory indicate that serum cystathionine levels increase markedly after a methionine load. One might expect that the degree of elevation of serum cystathionine would be less in heterozygotes for cystathionine P-synthase and that such serum cystathionine levels would also be useful in identifying such heterozygotes. Finally, the ratio of the degree of elevation of total homocysteine to the degree of elevation of cystathionine might be much higher in heterozygotes than in normal subjects and might be the best discriminator between heterozygotes and normal subjects. The ability to recognize such heterozygotes may be important, because some studies indicate that they are responsible for a large percentage of younger patients (age 4 0 ) with all forms of vascular disease."
Our serum assay for cystathionine may also prove to be useful in other clinical situations. For instance, it has been shown in pyridoxine deficiency that urine cystathionine levels are increased. 32 We speculate that serum cystathionine levels may be even more sensitive in detecting this deficiency. It is also possible that serum cystathionine levels will prove to be a useful marker for following patients with neuroblastomas, because previous studies have shown that elevated levels of urine cystathionine are present in approximately 50% to 80% of patients with neuroblastoma and, as the stage of disease increases, the incidence and magnitude of urinary cystathionine excretion increases.36 Further studies are needed to determine if elevated serum cystathionine levels would be a diagnostic marker for neuroblastoma and could be used to follow disease status,
